TNSN07436A1 - Motilides - Google Patents

Motilides

Info

Publication number
TNSN07436A1
TNSN07436A1 TNP2007000436A TNSN07436A TNSN07436A1 TN SN07436 A1 TNSN07436 A1 TN SN07436A1 TN P2007000436 A TNP2007000436 A TN P2007000436A TN SN07436 A TNSN07436 A TN SN07436A TN SN07436 A1 TNSN07436 A1 TN SN07436A1
Authority
TN
Tunisia
Prior art keywords
motilides
prokinesics
compounds
useful
formula
Prior art date
Application number
TNP2007000436A
Other languages
English (en)
Inventor
Yaoquan Liu
Christopher Carreras
David C Myles
Yong Li
Simon James Shaw
Hong Fu
Yue Chen
Hao Zheng
Yandong Li
Mark A Burlingame
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN07436A1 publication Critical patent/TNSN07436A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des composés, ayant une structure de formule (I) dans laquelle RA, RB, RC, RD, RE et RF sont tels que définis dans le présent mémoire, sont utiles comme agents prokinésiques.
TNP2007000436A 2005-05-24 2007-11-23 Motilides TNSN07436A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68461205P 2005-05-24 2005-05-24
US71540605P 2005-09-08 2005-09-08
US74889805P 2005-12-08 2005-12-08
US11/416,519 US7582611B2 (en) 2005-05-24 2006-05-02 Motilide compounds
PCT/US2006/017672 WO2006127252A1 (fr) 2005-05-24 2006-05-08 Composés de type motilide

Publications (1)

Publication Number Publication Date
TNSN07436A1 true TNSN07436A1 (fr) 2009-03-17

Family

ID=37452327

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000436A TNSN07436A1 (fr) 2005-05-24 2007-11-23 Motilides

Country Status (20)

Country Link
US (1) US7582611B2 (fr)
EP (1) EP1888082B1 (fr)
JP (1) JP4197359B2 (fr)
KR (1) KR100956465B1 (fr)
AP (1) AP2337A (fr)
AU (1) AU2006249555B2 (fr)
BR (1) BRPI0611374A2 (fr)
CA (1) CA2609494C (fr)
CU (1) CU23750B7 (fr)
EA (1) EA014711B1 (fr)
ES (1) ES2392860T3 (fr)
GE (1) GEP20094854B (fr)
HK (1) HK1117739A1 (fr)
IL (1) IL186752A (fr)
MA (1) MA29485B1 (fr)
MX (1) MX2007014255A (fr)
NO (1) NO20076464L (fr)
NZ (1) NZ562891A (fr)
TN (1) TNSN07436A1 (fr)
WO (1) WO2006127252A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0619556A2 (pt) * 2005-12-08 2011-10-04 Pfizer processo para desmetilação de grupo 3' -dimetil amino de compostos eritromicina
CN101528765B (zh) 2006-09-11 2015-04-22 欧塞拉治疗有限公司 用于治疗胃肠动力障碍病症的促胃动素受体的大环拮抗剂
MX2009005977A (es) * 2006-12-05 2009-06-17 Pfizer Polimorfos de motilida.
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102317280B (zh) 2009-02-27 2014-07-23 拉夸里亚创药株式会社 具有胃动素受体激动活性的羟基吲哚衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (fr) 2010-02-01 2014-07-23 Novartis AG Dérivés de pyrazolo[5,1-b]utilisés en tant qu'antagonistes du récepteur de crf-1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983103A (en) 1973-01-19 1976-09-28 Pliva Pharmaceutical And Chemical Works N-(Benzenesulfonyl)-erythromycylamine derivatives
YU35369B (en) 1973-01-19 1980-12-31 Pliva Zagreb Process for preparing n-(benzenesulfonyl)-erythromycilamine derivatives
US3855200A (en) 1973-04-23 1974-12-17 Polska Akademia Nauk Instytut Process for preparing 8-hydroxyerthromycin a and intermediates therefor
YU35363B (en) 1974-01-14 1980-12-31 Pliva Zagreb Process for obtaining n-(benzene-sulfonyl)-5-0desosaminyl-erythromycilamine derivatives
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
IT1196041B (it) 1984-03-08 1988-11-10 Pierrel Spa Emichetali di (8s)-8-fluoroeritromicine,il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che contengono i prodotti
JPS60218321A (ja) 1984-04-13 1985-11-01 Satoshi Omura 消化管収縮運動促進剤
US5175150A (en) 1985-08-31 1992-12-29 Kitasato, Kenkyusho Erythromycin derivative
US5008249A (en) 1985-08-31 1991-04-16 Kitasato Kenkyusho Therapeutic method of stimulating digestive tract contractile motion in mammals
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5554605A (en) 1991-04-09 1996-09-10 Abbott Laboratories Macrocyclic lactam prokinetic agents
JPH06509326A (ja) 1991-04-09 1994-10-20 アボツト・ラボラトリーズ 大環式ラクタムプロキネティック剤
DE4200145A1 (de) * 1992-01-07 1993-07-08 Kali Chemie Pharma Gmbh 7,10-epoxy-oxacyclododecan-derivate, verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JP2662094B2 (ja) 1992-01-21 1997-10-08 アボツト・ラボラトリーズ ４″−デオキシエリスロマイシン誘導体
EP0561413B1 (fr) 1992-03-19 1996-06-05 Takeda Chemical Industries, Ltd. Dérivés d'erythromycin, leur préparation et leur utilisation
MY113693A (en) 1992-05-26 2002-05-31 Chugai Pharmaceutical Co Ltd Erythromycin derivatives having an enterokinesis stimulating action
ZA966601B (en) 1995-08-03 1997-02-19 Chugai Pharmaceutical Co Ltd Process for producing erythromycin derivatives.
EP0918783A1 (fr) 1996-05-07 1999-06-02 Abbott Laboratories Erythromycines 6-o substituees et leur procede de preparation
US5712253A (en) 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
JP2000511063A (ja) * 1996-07-05 2000-08-29 バイオティカ テクノロジー リミティド ポリケチド類及びそれらの合成
HRP960497B1 (en) * 1996-10-28 2003-08-31 Pliva Pharm & Chem Works 9-n-ethenyl derivatives of 9(s)-erythromycylamine
US5922849A (en) 1996-11-22 1999-07-13 Abbott Laboratories Process for preparation of N-demethyl-4"-deoxy-erthromycins A and B
WO1999021868A1 (fr) 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
US6084079A (en) 1998-05-15 2000-07-04 Keyes; Robert F. Process for preparing N-demethyl-N-alkyl erythromycin derivatives
KR100317907B1 (ko) * 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
IT1306205B1 (it) * 1999-01-15 2001-05-30 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
CA2399198A1 (fr) 2000-02-18 2001-08-23 Christopher Carreras Composes motilides
CA2420847C (fr) * 2000-09-01 2008-02-05 Chugai Seiyaku Kabushiki Kaisha Procede permettant la production d'un derive d'erythromycine
US20020094962A1 (en) 2000-12-01 2002-07-18 Gary Ashley Motilide compounds
JP2004530108A (ja) 2001-02-15 2004-09-30 コーサン バイオサイエンシーズ， インコーポレイテッド 治療効力を評価するための方法
JP2002241391A (ja) 2001-02-15 2002-08-28 Taisho Pharmaceut Co Ltd エリスロマイシンａ誘導体
SI1532131T1 (sl) 2002-08-29 2009-04-30 Pfizer Motilidne spojine
US20050113319A1 (en) 2003-08-26 2005-05-26 Christopher Carreras 11-Deoxy-6,9-ether erythromycin compounds
US7407941B2 (en) 2003-08-26 2008-08-05 Pfizer, Inc. N-desmethyl-N-substituted-11-deoxyerythromycin compounds
EP1682563A1 (fr) * 2003-10-30 2006-07-26 Rib-X Pharmaceuticals, Inc. Composes heterocycliques macrolidiques bifonctionnels et leurs procedes de preparation et d'utilisation
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
US20060075011A1 (en) * 2004-09-23 2006-04-06 Fujitsu Limited System and method for optimizing polynomial expressions in a processing environment
TW200633714A (en) 2004-12-28 2006-10-01 Chugai Pharmaceutical Co Ltd Drugs for the treatment and/or prophylaxis of gastroparesis symptom

Also Published As

Publication number Publication date
JP4197359B2 (ja) 2008-12-17
AU2006249555A8 (en) 2006-11-30
NO20076464L (no) 2008-02-22
MX2007014255A (es) 2008-01-22
US20060270616A1 (en) 2006-11-30
CA2609494C (fr) 2010-12-21
KR20080013922A (ko) 2008-02-13
EA200702290A1 (ru) 2008-04-28
NZ562891A (en) 2011-01-28
CU20070261A7 (es) 2009-07-16
EP1888082A4 (fr) 2008-12-17
JP2008542268A (ja) 2008-11-27
KR100956465B1 (ko) 2010-05-07
IL186752A (en) 2011-10-31
HK1117739A1 (en) 2009-01-23
IL186752A0 (en) 2008-02-09
AP2337A (en) 2011-12-14
ES2392860T3 (es) 2012-12-14
AP2007004220A0 (en) 2007-10-31
AU2006249555B2 (en) 2009-07-16
BRPI0611374A2 (pt) 2010-08-31
CA2609494A1 (fr) 2006-11-30
AU2006249555A1 (en) 2006-11-30
GEP20094854B (en) 2009-12-10
CU23750B7 (es) 2012-01-31
US7582611B2 (en) 2009-09-01
EP1888082B1 (fr) 2012-09-12
MA29485B1 (fr) 2008-05-02
EA014711B1 (ru) 2011-02-28
WO2006127252A1 (fr) 2006-11-30
EP1888082A1 (fr) 2008-02-20

Similar Documents

Publication Publication Date Title
TNSN07436A1 (fr) Motilides
EA200801560A1 (ru) Бифенилкарбоксамиды
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
MA31759B1 (fr) Compose amide
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
DK1631295T3 (da) Anvendelse af kondenserede heterocykliske forbindelser som SCCE-inhibitorer ved behandling af hudsygdomme
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200901463A1 (ru) Ингибиторы вирусной полимеразы
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
WO2007085895A3 (fr) Inhibiteurs fap
EA200601002A1 (ru) 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
EA200702567A1 (ru) Ингибиторы дипептидил пептидазы iv, основанные на пирролопиридине
EA200700188A1 (ru) Производные замещенного 2-алкилхиназолинона как ингибиторы parp
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200800357A1 (ru) Новые фармацевтические соединения
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
CY1108399T1 (el) Τετραϋδροπυριδοθειοφαινια
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина